BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc. – The demand for minimally invasive surgical treatments is increasing as a result of benefits such as less discomfort, shorter recovery times, and smaller incisions

Wilmington, Delaware, United States, Transparency Market Research Inc. – Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disorder of central nervous system which was previously known as Devic disease or neuromyelitis optica (NMO).

Wilmington, Delaware, United States, Transparency Market Research Inc. – Transparency Market Research points out that the competitive landscape in the global human growth hormone market is fairly consolidated. Players continue to focus on developing products with minimal side effects

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), will post its Q2 financial results after market open on August 29, 2022.

ArcutisBiotherapeutics,Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno- dermatology, today announced the enrollment of the last subject in its INTEGUMENT-2 pivotal Phase 3 trial of roflumilast cream 0.15% in adults and children with atopicdermatitis (AD).

Seer, Inc. (Nasdaq: SEER) today announced the publication of a study demonstrating the performance of the technology underlying the Proteograph™ Product Suite for deep, unbiased, precise, scalable proteomics.

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that the first patient was treated in a first-in-human Phase 1 study to assess the safety and immune biomarkers of UNO therapy.

Windtree Therapeutics, Inc. announced it has entered into a global licensing agreement with Lee’s Pharmaceutical Limited, and its affiliate Zhaoke Pharmaceutical Co. Ltd., for the development and commercialization of Windtree’s acute pulmonary pipeline treatments KL4 surfactant and drug/device combination, AEROSURF®, for the treatment of preterm infants with respiratory distress syndrome and other potential applications.

Nanostics Inc., a precision health diagnostics company, is excited to announce today that it has received the CE-IVD Mark for its ClarityDX Prostate® test.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), today announced dosing of the first patient in its Phase 2a study (‘201 trial’) evaluating IkT-148009, the Company’s novel Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson’s disease.